On Demand 2024 Thursday Program

You can earn up to 6.75 AMA PRA Category 1 Credit(s)TM.

Price: FREE for meeting attendees who purchased a ticket to the Thursday Program, otherwise $99 members, $125 non-members

This year’s Thursday Program at the ACAAI annual meeting will feature an entire day examining the latest developments in asthma care.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 6.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Demonstrate increased knowledge of which readily obtainable biomarkers best predict asthma exacerbations.
  • Identify how FeNO can be utilized in practice to optimize the information it provides
  • Recognize how race-based spirometry values were established and whether they should be utilized or not. Relate increased knowledge of how MART and biologics can best be utilized in the pediatric population, which has less data on their use.
  • Surmise proposed changes to the forthcoming Severe Asthma Practice Parameter.
  • Apply personalized asthma therapy for patients of different ages and ethnicities.
  • Formulate the use of biologics in the real world based on knowledge of when and why to stop.
  • Summarize current guidance on clinical “remission” on treatment.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 6.75 AMA PRA Category 1 Credit™
  • 6.75 Attendance
  • 6.75 CBRN
Course opens: 
11/11/2024
Course expires: 
11/10/2027
Cost:
$125.00
Rating: 
0

Jay A. Lieberman, MD, FACAAI
Thomas B. Casale, MD, FACAAI
Njira Lugogo, MD
Bridgette L. Jones, MD
Leonard B. Bacharier, MD, FACAAI
Wanda Phipatanakul, MD, MS, FACAAI
Tamara T. Perry, MD
Matthew A. Rank, MD, FACAAI
Kristin C. Sokol, MD, FACAAI
William C. Anderson, III, MD, FACAAI
Giselle S. Mosnaim, MD, MS, FACAAI
Jennifer A. Shih, MD, FACAAI
Mauli B. Desai, MD, FACAAI
John J. Oppenheimer, MD, FACAAI
Michael E. Wechsler, MD, MMSc
Marcus S. Shaker, MD, MSc, FACAAI
Gailen D. Marshall, Jr,, MD, PhD, FACAAI

Available Credit

  • 6.75 AMA PRA Category 1 Credit™
  • 6.75 Attendance
  • 6.75 CBRN

Price

Cost:
$125.00
Please login or create an account to take this course.